---
title: "BIOR.US (BIOR.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BIOR.US/news.md"
symbol: "BIOR.US"
name: "BIOR.US"
parent: "https://longbridge.com/en/quote/BIOR.US.md"
datetime: "2026-03-12T05:37:33.710Z"
locales:
  - [en](https://longbridge.com/en/quote/BIOR.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BIOR.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BIOR.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/BIOR.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/BIOR.US/news.md)


# BIOR.US (BIOR.US) — Related News

### [16:13 ETNotice of the Extraordinary General Meeting of Bioretec Ltd](https://longbridge.com/en/news/278609932.md)
*2026-03-10T20:13:59.000Z*
> Bioretec Ltd has announced an Extraordinary General Meeting scheduled for March 27, 2026, to discuss a proposed rights o

### [Bioretec Ltd's financials for Jan-Dec 2025: Net sales EUR 3,522k (-22.5% vs 2024), EBITDA EUR -8,476k. Strategy update for 2026–2028.](https://longbridge.com/en/news/275869613.md)
*2026-02-13T08:07:46.000Z*
> Bioretec Ltd reported its financial results for January to December 2025, showing net sales of EUR 3,522k, a 22.5% decli

### [Bioretec Oyj hat eine Aktualisierung ihres Finanzkalenders veröffentlicht](https://longbridge.com/en/news/275331973.md)
*2026-02-09T14:30:27.000Z*
> Bioretec Oyj will release its financial report for the fiscal year 2025 on February 13, 2026, at approximately 9:30 AM E

### [WuXi Biologics and Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases](https://longbridge.com/en/news/274078631.md)
*2026-01-29T02:40:33.000Z*
> WuXi Biologics has partnered with Sinorda Biomedicine to develop SND006, a bispecific antibody for autoimmune diseases. 

### [Biotalys and 21st.BIO partner to advance biocontrol production; Biotalys updates funding plans for next phase of development.](https://longbridge.com/en/news/273471372.md)
*2026-01-23T06:01:23.000Z*
> Biotalys has recently shared an update on its strategy to secure funding for the next stage of development. The company 

### [RCS - Ondine Biomedical - Steriwave Expands into ENT Surgery in Spain](https://longbridge.com/en/news/273351776.md)
*2026-01-22T09:42:39.000Z*
> Ondine Biomedical Inc. has announced the expansion of its Steriwave® nasal photodisinfection technology into ENT surgery

### [Biocon now holds 98% of Biocon Biologics' equity share capital](https://longbridge.com/en/news/273248302.md)
*2026-01-21T14:45:49.000Z*
> Biocon now holds 98% of Biocon Biologics' equity share capital

### [Biora Therapeutics completes restructuring process, now privately held; aims to speed up BioJet™ platform development.](https://longbridge.com/en/news/239432971.md)
*2025-05-08T21:52:57.000Z*
> After completing restructuring, Biora has transitioned into a privately held firm, equipped with long-term funding aimed

### [Biora Therapeutics completes successful restructuring process to emerge as privately held company, focusing on BioJet™ platform.](https://longbridge.com/en/news/238989774.md)
*2025-05-06T21:27:01.000Z*
> After completing its restructuring, Biora now operates as a privately held company. The company has secured long-term fi

### [Biora Therapeutics finishes restructuring, now privately held with funds to boost BioJet™ platform development.](https://longbridge.com/en/news/238685666.md)
*2025-05-04T19:33:22.000Z*
> After completing a restructuring process, Biora has transitioned into a privately owned company. The company has secured